S&P 500   3,900.21 (+2.34%)
DOW   31,576.58 (+2.08%)
QQQ   322.19 (+2.56%)
AAPL   126.23 (+4.10%)
MSFT   236.87 (+1.93%)
FB   261.58 (+1.54%)
GOOGL   2,057.81 (+1.78%)
TSLA   713.99 (+5.70%)
AMZN   3,123.79 (+1.00%)
NVDA   548.79 (+0.04%)
BABA   239.83 (+0.87%)
CGC   34.75 (+6.11%)
GE   13.21 (+5.34%)
MU   94.43 (+3.17%)
NIO   49.86 (+8.91%)
AMD   85.71 (+1.42%)
T   28.28 (+1.40%)
F   12.02 (+2.74%)
ACB   11.18 (+6.27%)
DIS   194.26 (+2.76%)
BA   223.38 (+5.36%)
NFLX   550.45 (+2.15%)
BAC   35.55 (+2.42%)
S&P 500   3,900.21 (+2.34%)
DOW   31,576.58 (+2.08%)
QQQ   322.19 (+2.56%)
AAPL   126.23 (+4.10%)
MSFT   236.87 (+1.93%)
FB   261.58 (+1.54%)
GOOGL   2,057.81 (+1.78%)
TSLA   713.99 (+5.70%)
AMZN   3,123.79 (+1.00%)
NVDA   548.79 (+0.04%)
BABA   239.83 (+0.87%)
CGC   34.75 (+6.11%)
GE   13.21 (+5.34%)
MU   94.43 (+3.17%)
NIO   49.86 (+8.91%)
AMD   85.71 (+1.42%)
T   28.28 (+1.40%)
F   12.02 (+2.74%)
ACB   11.18 (+6.27%)
DIS   194.26 (+2.76%)
BA   223.38 (+5.36%)
NFLX   550.45 (+2.15%)
BAC   35.55 (+2.42%)
S&P 500   3,900.21 (+2.34%)
DOW   31,576.58 (+2.08%)
QQQ   322.19 (+2.56%)
AAPL   126.23 (+4.10%)
MSFT   236.87 (+1.93%)
FB   261.58 (+1.54%)
GOOGL   2,057.81 (+1.78%)
TSLA   713.99 (+5.70%)
AMZN   3,123.79 (+1.00%)
NVDA   548.79 (+0.04%)
BABA   239.83 (+0.87%)
CGC   34.75 (+6.11%)
GE   13.21 (+5.34%)
MU   94.43 (+3.17%)
NIO   49.86 (+8.91%)
AMD   85.71 (+1.42%)
T   28.28 (+1.40%)
F   12.02 (+2.74%)
ACB   11.18 (+6.27%)
DIS   194.26 (+2.76%)
BA   223.38 (+5.36%)
NFLX   550.45 (+2.15%)
BAC   35.55 (+2.42%)
S&P 500   3,900.21 (+2.34%)
DOW   31,576.58 (+2.08%)
QQQ   322.19 (+2.56%)
AAPL   126.23 (+4.10%)
MSFT   236.87 (+1.93%)
FB   261.58 (+1.54%)
GOOGL   2,057.81 (+1.78%)
TSLA   713.99 (+5.70%)
AMZN   3,123.79 (+1.00%)
NVDA   548.79 (+0.04%)
BABA   239.83 (+0.87%)
CGC   34.75 (+6.11%)
GE   13.21 (+5.34%)
MU   94.43 (+3.17%)
NIO   49.86 (+8.91%)
AMD   85.71 (+1.42%)
T   28.28 (+1.40%)
F   12.02 (+2.74%)
ACB   11.18 (+6.27%)
DIS   194.26 (+2.76%)
BA   223.38 (+5.36%)
NFLX   550.45 (+2.15%)
BAC   35.55 (+2.42%)
Log in
NASDAQ:MRUS

Merus Competitors

$23.70
+1.20 (+5.33 %)
(As of 03/1/2021 12:00 PM ET)
Add
Compare
Today's Range
$22.78
Now: $23.70
$23.98
50-Day Range
$20.00
MA: $24.43
$29.11
52-Week Range
$10.18
Now: $23.70
$31.27
Volume5,009 shs
Average Volume201,783 shs
Market Capitalization$748.99 million
P/E RatioN/A
Dividend YieldN/A
Beta0.83

Competitors

Merus (NASDAQ:MRUS) Vs. ITCI, XNCR, TARO, PRLD, IGMS, and GBT

Should you be buying MRUS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Merus, including Intra-Cellular Therapies (ITCI), Xencor (XNCR), Taro Pharmaceutical Industries (TARO), Prelude Therapeutics (PRLD), IGM Biosciences (IGMS), and Global Blood Therapeutics (GBT).

Merus (NASDAQ:MRUS) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Insider and Institutional Ownership

62.6% of Merus shares are held by institutional investors. Comparatively, 79.1% of Intra-Cellular Therapies shares are held by institutional investors. 7.4% of Merus shares are held by insiders. Comparatively, 18.2% of Intra-Cellular Therapies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Merus and Intra-Cellular Therapies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merus$31.13 million24.06$-55,150,000.00($2.33)-10.17
Intra-Cellular Therapies$60,000.0047,306.58$-147,720,000.00($2.68)-13.21

Merus has higher revenue and earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Merus and Intra-Cellular Therapies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merus01202.67
Intra-Cellular Therapies00703.00

Merus currently has a consensus price target of $23.50, suggesting a potential downside of 0.97%. Intra-Cellular Therapies has a consensus price target of $47.4286, suggesting a potential upside of 31.89%. Given Intra-Cellular Therapies' stronger consensus rating and higher possible upside, analysts clearly believe Intra-Cellular Therapies is more favorable than Merus.

Profitability

This table compares Merus and Intra-Cellular Therapies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merus-295.98%-78.70%-36.12%
Intra-Cellular Therapies-1,985.32%-48.27%-42.56%

Risk & Volatility

Merus has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500.

Summary

Intra-Cellular Therapies beats Merus on 8 of the 14 factors compared between the two stocks.

Merus (NASDAQ:MRUS) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Earnings & Valuation

This table compares Merus and Xencor's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merus$31.13 million24.06$-55,150,000.00($2.33)-10.17
Xencor$156.70 million17.81$26.88 million$0.46104.72

Xencor has higher revenue and earnings than Merus. Merus is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Merus has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.

Profitability

This table compares Merus and Xencor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merus-295.98%-78.70%-36.12%
Xencor-113.40%-13.56%-12.03%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Merus and Xencor, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merus01202.67
Xencor20702.56

Merus presently has a consensus price target of $23.50, suggesting a potential downside of 0.97%. Xencor has a consensus price target of $47.1111, suggesting a potential downside of 2.14%. Given Merus' stronger consensus rating and higher probable upside, research analysts plainly believe Merus is more favorable than Xencor.

Insider & Institutional Ownership

62.6% of Merus shares are owned by institutional investors. 7.4% of Merus shares are owned by company insiders. Comparatively, 3.7% of Xencor shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Merus (NASDAQ:MRUS) and Taro Pharmaceutical Industries (NYSE:TARO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, institutional ownership, dividends, valuation and earnings.

Institutional and Insider Ownership

62.6% of Merus shares are held by institutional investors. Comparatively, 11.2% of Taro Pharmaceutical Industries shares are held by institutional investors. 7.4% of Merus shares are held by insiders. Comparatively, 13.8% of Taro Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Merus and Taro Pharmaceutical Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merus-295.98%-78.70%-36.12%
Taro Pharmaceutical Industries-45.94%10.36%8.38%

Earnings & Valuation

This table compares Merus and Taro Pharmaceutical Industries' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merus$31.13 million24.06$-55,150,000.00($2.33)-10.17
Taro Pharmaceutical Industries$644.77 million4.33$244.24 million$6.3511.50

Taro Pharmaceutical Industries has higher revenue and earnings than Merus. Merus is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Merus and Taro Pharmaceutical Industries, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merus01202.67
Taro Pharmaceutical Industries00103.00

Merus presently has a consensus price target of $23.50, indicating a potential downside of 0.97%. Taro Pharmaceutical Industries has a consensus price target of $81.00, indicating a potential upside of 12.83%. Given Taro Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts plainly believe Taro Pharmaceutical Industries is more favorable than Merus.

Risk & Volatility

Merus has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Taro Pharmaceutical Industries has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.

Summary

Taro Pharmaceutical Industries beats Merus on 10 of the 14 factors compared between the two stocks.

Prelude Therapeutics (NASDAQ:PRLD) and Merus (NASDAQ:MRUS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations.

Profitability

This table compares Prelude Therapeutics and Merus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prelude TherapeuticsN/AN/AN/A
Merus-295.98%-78.70%-36.12%

Analyst Ratings

This is a summary of recent ratings and target prices for Prelude Therapeutics and Merus, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prelude Therapeutics03002.00
Merus01202.67

Prelude Therapeutics presently has a consensus price target of $41.3333, indicating a potential downside of 37.43%. Merus has a consensus price target of $23.50, indicating a potential downside of 0.97%. Given Merus' stronger consensus rating and higher possible upside, analysts clearly believe Merus is more favorable than Prelude Therapeutics.

Insider and Institutional Ownership

76.2% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 62.6% of Merus shares are held by institutional investors. 7.4% of Merus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Prelude Therapeutics and Merus' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prelude TherapeuticsN/AN/AN/AN/AN/A
Merus$31.13 million24.06$-55,150,000.00($2.33)-10.17

Prelude Therapeutics has higher earnings, but lower revenue than Merus.

Summary

Merus beats Prelude Therapeutics on 5 of the 9 factors compared between the two stocks.

Merus (NASDAQ:MRUS) and IGM Biosciences (NASDAQ:IGMS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, dividends, profitability and risk.

Institutional and Insider Ownership

62.6% of Merus shares are owned by institutional investors. Comparatively, 47.6% of IGM Biosciences shares are owned by institutional investors. 7.4% of Merus shares are owned by insiders. Comparatively, 79.3% of IGM Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Merus and IGM Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merus-295.98%-78.70%-36.12%
IGM BiosciencesN/A-33.30%-30.28%

Earnings & Valuation

This table compares Merus and IGM Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merus$31.13 million24.06$-55,150,000.00($2.33)-10.17
IGM BiosciencesN/AN/A$-43,130,000.00($4.80)-18.88

IGM Biosciences has lower revenue, but higher earnings than Merus. IGM Biosciences is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Merus has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of -1.12, suggesting that its stock price is 212% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Merus and IGM Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merus01202.67
IGM Biosciences01702.88

Merus presently has a consensus price target of $23.50, indicating a potential downside of 0.97%. IGM Biosciences has a consensus price target of $96.00, indicating a potential upside of 6.63%. Given IGM Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe IGM Biosciences is more favorable than Merus.

Summary

IGM Biosciences beats Merus on 8 of the 13 factors compared between the two stocks.

Global Blood Therapeutics (NASDAQ:GBT) and Merus (NASDAQ:MRUS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Risk & Volatility

Global Blood Therapeutics has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500. Comparatively, Merus has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Global Blood Therapeutics and Merus, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Global Blood Therapeutics051202.71
Merus01202.67

Global Blood Therapeutics presently has a consensus price target of $93.8235, suggesting a potential upside of 115.04%. Merus has a consensus price target of $23.50, suggesting a potential downside of 0.97%. Given Global Blood Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Global Blood Therapeutics is more favorable than Merus.

Valuation and Earnings

This table compares Global Blood Therapeutics and Merus' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Global Blood Therapeutics$2.11 million1,280.14$-266,770,000.00($4.71)-9.28
Merus$31.13 million24.06$-55,150,000.00($2.33)-10.17

Merus has higher revenue and earnings than Global Blood Therapeutics. Merus is trading at a lower price-to-earnings ratio than Global Blood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Global Blood Therapeutics and Merus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Global Blood Therapeutics-332.94%-56.43%-39.32%
Merus-295.98%-78.70%-36.12%

Insider & Institutional Ownership

62.6% of Merus shares are held by institutional investors. 4.3% of Global Blood Therapeutics shares are held by insiders. Comparatively, 7.4% of Merus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Merus beats Global Blood Therapeutics on 8 of the 14 factors compared between the two stocks.


Merus Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$35.41+0.1%$2.84 billion$60,000.00-11.00Earnings Announcement
Gap Down
Xencor logo
XNCR
Xencor
1.0$48.17+2.3%$2.83 billion$156.70 million-34.41Earnings Announcement
Analyst Revision
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$73.00+2.1%$2.74 billion$644.77 million-10.41Increase in Short Interest
PRLD
Prelude Therapeutics
1.0$65.99+5.5%$2.72 billionN/A0.00Upcoming Earnings
IGMS
IGM Biosciences
1.5$90.61+3.5%$2.68 billionN/A-38.56Gap Down
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.6$43.71+2.5%$2.63 billion$2.11 million-9.46Earnings Announcement
Analyst Revision
News Coverage
Amarin logo
AMRN
Amarin
1.6$6.68+0.9%$2.62 billion$429.76 million-133.57Earnings Announcement
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.84+0.1%$2.52 billion$25 million-8.77Gap Down
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$71.08+5.2%$2.52 billionN/A-26.42
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$152.95+3.1%$2.46 billion$120.28 million-154.49Decrease in Short Interest
Cryoport logo
CYRX
Cryoport
1.3$62.55+5.0%$2.36 billion$33.94 million-107.84
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$36.38+3.1%$2.29 billion$15 million-19.05Earnings Announcement
Analyst Revision
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$42.56+2.0%$2.08 billion$963.01 million13.22
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$23.49+4.4%$2.04 billionN/A-8.36Gap Down
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.6$29.15+7.4%$2.02 billion$23.90 million-18.11Earnings Announcement
Analyst Report
Gap Down
HRMY
Harmony Biosciences
1.3$35.98+1.4%$2.02 billionN/A0.00Upcoming Earnings
Gap Down
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.0$61.19+2.1%$2.00 billionN/A-33.99Gap Down
Generation Bio logo
GBIO
Generation Bio
1.4$39.26+11.1%$1.95 billionN/A0.00Upcoming Earnings
Analyst Report
Analyst Revision
Gap Down
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$120.12+0.9%$1.87 billionN/A-10.85Earnings Announcement
Analyst Report
Analyst Revision
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.7$26.42+1.1%$1.84 billion$103.54 million-19.86News Coverage
ADCT
ADC Therapeutics
1.6$27.02+1.6%$1.83 billion$2.34 million-11.45Upcoming Earnings
Gap Up
Endo International logo
ENDP
Endo International
1.4$7.71+2.9%$1.83 billion$2.91 billion-11.34Earnings Announcement
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
2.0$14.06+0.4%$1.78 billion$320,000.00-9.56Earnings Announcement
Analyst Revision
News Coverage
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.1$60.49+0.5%$1.78 billion$970,000.000.00Analyst Report
Increase in Short Interest
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.5$26.69+1.6%$1.75 billion$410,000.00-5.80Analyst Upgrade
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.68+7.9%$1.74 billion$34.51 million-17.68Upcoming Earnings
Shattuck Labs logo
STTK
Shattuck Labs
1.1$41.38+0.2%$1.72 billionN/A0.00Upcoming Earnings
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$34.37+0.6%$1.71 billionN/A-3.72
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$41.58+1.1%$1.71 billionN/A0.00
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
1.3$54.36+10.1%$1.70 billionN/A0.00Upcoming Earnings
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.3$8.83+0.9%$1.70 billion$82.27 million-21.54
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.2$37.88+0.7%$1.68 billionN/A0.00Upcoming Earnings
Gap Down
Zymeworks logo
ZYME
Zymeworks
1.8$37.74+3.8%$1.68 billion$29.54 million-10.01Earnings Announcement
Increase in Short Interest
Analyst Revision
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.8$41.98+3.6%$1.66 billionN/A0.00Decrease in Short Interest
Gap Down
Frequency Therapeutics logo
FREQ
Frequency Therapeutics
1.3$51.38+4.2%$1.66 billion$28.95 million-73.40Gap Down
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$18.07+0.1%$1.65 billion$145.97 million-7.32Earnings Announcement
Analyst Revision
News Coverage
ORGO
Organogenesis
1.0$15.90+4.3%$1.64 billion$260.98 million-265.00Gap Down
uniQure logo
QURE
uniQure
1.9$37.74+2.8%$1.63 billion$7.28 million-10.01Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.8$29.02+0.2%$1.63 billionN/A0.00Upcoming Earnings
Gap Up
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$49.47+8.8%$1.62 billionN/A0.00Gap Down
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.20+3.7%$1.62 billion$1.63 billion12.68Earnings Announcement
Analyst Report
Unusual Options Activity
NKTX
Nkarta
1.6$49.27+1.0%$1.59 billionN/A0.00Upcoming Earnings
Kura Oncology logo
KURA
Kura Oncology
1.8$29.73+5.8%$1.59 billionN/A-18.24Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.3$30.42+1.3%$1.57 billion$175.34 million-17.89Analyst Downgrade
ATBPD
Antibe Therapeutics
0.1$3.98+9.0%$1.54 billion$7.51 million-6.63
OLMA
Olema Pharmaceuticals
1.7$40.26+0.8%$1.54 billionN/A0.00
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.0$32.71+7.4%$1.52 billion$6.20 million-14.35
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.5$9.57+3.6%$1.48 billion$428.41 million13.87
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$35.05+0.3%$1.42 billionN/A-11.80Earnings Announcement
Analyst Report
Decrease in Short Interest
Gap Down
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$26.24+2.4%$1.42 billion$392.76 million10.89Earnings Announcement
Analyst Revision
This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.